Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
20 Settembre 2023 - 2:00PM
Business Wire
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders, today announced that it will
present at the Cantor Fitzgerald Global Healthcare Conference and
the LD Micro Main Event Conference.
Management will participate in a panel presentation at the
Cantor Fitzgerald Conference where they will provide an overview of
the Company’s multi-cytokine inhibitor platform, and will give a
full corporate and clinical overview including upcoming milestones
at the LD Micro Main Event Conference. Management will be available
for one-on-one meetings during both conferences.
Conference: Cantor Fitzgerald Global Healthcare
Conference Location: InterContinental Barclay Hotel, New
York City Date: Wednesday, September 27 Time: 5:00 am
Pacific Time | 8:00 am Eastern Time
Conference: LD Micro Invitational Conference
Location: Luxe Hotel, Los Angeles Date: Tuesday,
October 3 Time: 11:00 am Pacific Time | 2:00 pm Eastern
Time
The presentation at the LD Micro conference will be
live-streamed on the event website at
https://me23.sequireevents.com/.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel first-in-class immunomodulatory assets targeting
immuno-inflammatory pathways. EQ101: a tri-specific cytokine
inhibitor that selectively targets IL-2, IL-9, and IL-15; currently
under evaluation in a Phase 2 proof-of-concept clinical study of
patients with alopecia areata. EQ102: a bi-specific cytokine
inhibitor that selectively targets IL-15 and IL-21; currently under
evaluation in a Phase 1 first-in-human clinical study to include
healthy volunteers and celiac disease patients. Itolizumab: a
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells;
currently under evaluation in a Phase 3 clinical study of patients
with acute graft-versus-host disease (aGVHD) and a Phase 1b
clinical study of patients with lupus/lupus nephritis. Equillium
acquired rights to itolizumab through an exclusive partnership with
Biocon Limited and has entered a strategic partnership with Ono
Pharmaceutical Co., Ltd. for the development and commercialization
of itolizumab under an option and asset purchase agreement.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of Equillium’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Risks that contribute
to the uncertain nature of the forward-looking statements include:
risks and uncertainties regarding whether, when and on what terms
Equillium repurchases its shares of common stock under the program;
changes in market conditions and alternative uses of Equillium’s
capital, including having to use cash in ways or on timing other
than expected; the sufficiency of Equillium’s capital to fund
certain clinical development efforts and whether anticipated
milestones are able to be achieved; whether Equillium is able to
grow its business and increase stockholder value over time; and
risks related to Ono’s decision to exercise its option, if ever, to
purchase itolizumab or terminate the asset purchase agreement.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in Equillium's
filings and reports, which may be accessed for free by visiting the
Securities and Exchange Commission’s website at www.sec.gov and on
Equillium’s website under the heading “Investors.” Investors should
take such risks into account and should not rely on forward-looking
statements when making investment decisions. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Equillium undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were made,
except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230920597056/en/
Investor Contact Michael Moore Vice President, Investor
Relations & Corporate Communications 619-302-4431
ir@equilliumbio.com
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Mag 2023 a Mag 2024